Business Wire

DNP Achieves Fine Pattern Resolution on EUV Lithography Photomasks for Beyond 2nm Generation

12.12.2024 02:37:00 CET | Business Wire | Press release

Share

Commences sample supply of high-NA EUV photomasks for next-generation semiconductors

Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) has successfully achieved the fine pattern resolution required for photomasks for logic semiconductors of the beyond 2nm (nm: 10-9 meter) generation1 that support Extreme Ultra-Violet (EUV) lithography, a cutting-edge process in semiconductor manufacturing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241208160921/en/

null

Image of photomask for beyond 2nm generation EUV lithography (Photo: Business Wire)

DNP has also completed the criteria evaluation for photomasks compatible with High-Numerical Aperture2, the application being considered for next-generation semiconductors beyond the 2nm generation, and has commenced the supply of evaluation photomasks. High-NA EUV lithography makes it possible to form fine patterns on silicon wafers with a higher resolution than previously possible, and is expected to lead to the realization of high-performance, low-power semiconductors.

[Development]

  • To realize photomasks for beyond 2nm generation EUV lithography, requires patterns 20% smaller than those for the 3nm generation. This refers not only to the size and shape of the patterns, and technology required to resolve fine patterns of all types on the face of the same mask. This includes not only standard straight and rectangular patterns but also increasingly complex curved patterns. DNP has achieved the pattern resolution required for the beyond 2nm generation by making repeated improvements based on the established 3nm generation manufacturing process.
  • Photomasks for high NA-EUV lithography require higher precision and finer processing than those for standard EUV lithography. DNP established and optimized a manufacturing process flow that differs from that for conventional EUV lithography photomasks.

[Going Forward]

DNP will continue to establish production technologies with the goal of commencing mass production of photomasks for 2nm generation logic semiconductors in FY 2027.

We will also continue to cooperate with imec to promote the development of photomask manufacturing technologies with an eye toward the 1nm generation.

1: Compliant with IRDS standards

2: Numerical Aperture (NA) is a number that indicates the brightness and resolution of an optical system. High-NA refers to the expansion of the lens NA of EUV exposure equipment from the conventional 0.33 to 0.55.

More Details

About DNP

DNP was established in 1876, and has become a leading global company that leverages print-based solutions to engineer fresh business opportunities while protecting the environment and creating a more vibrant world for all. We capitalize on core competencies in microfabrication and precision coating technology to provide products for the display, electronic device, and optical film markets. We have also developed new products, such as vapor chamber and reflect array that offer next-generation communication solutions for more people-friendly information society.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241208160921/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros Announces Publication of Phase 2 RAINBOW Study Data for Nizubaglustat in Molecular Genetics and Metabolism Journal5.6.2026 07:00:00 CEST | Press release

Phase 2 RAINBOW study data showed that treatment with nizubaglustat in patients with GM2 gangliosidosis (GM2) and Niemann-Pick type C disease (NPC) reduced disease progression and seizure burdenTopline results from the study announced in 2024 demonstrated that nizubaglustat was safe and well tolerated, with encouraging signs of efficacyThe published data further supports the two ongoing registrational Phase 3 studies with nizubaglustat in GM1/GM2 and NPC Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced the publication of clinical data from its Phase 2 (RAINBOW) study in the peer reviewed journal, Molecular Genetics & Metabolism. The published manuscript reports efficacy, safety, pharmacokinetic and pharmacodynamic data which evaluated nizubaglustat in patients with genetically confirmed GM2 gangliosidosis and NPC. As previously stated in the topline results announcemen

K-Startup Grand Challenge 2026: Korea's Full-Cycle Launchpad for Global Startups5.6.2026 03:00:00 CEST | Press release

KSGC 2026 provides end-to-end support - from market entry to sustainable growth - positioning Korea as the gateway for Asia expansion South Korea’s Ministry of SMEs and Startups (MSS) has opened applications for the K-Startup Grand Challenge (KSGC), the country’s premier government-backed acceleration program for international startups targeting Korea and Asia. Since 2016, KSGC has attracted 21,537 applicants from more than 100 countries, among the world's most recognized inbound programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604794426/en/ South Korea’s Ministry of SMEs and Startups (MSS) has opened applications for K-Startup Grand Challenge 2026, a government-backed global startup acceleration program providing end-to-end support for international startups (Image: KSGC) A Full-Cycle Acceleration Journey Unlike conventional programs that focus on a single moment of market entry, KSGC 2026 guides startups from ma

Empire State Building Observation Deck Celebrates Soccer with World’s Most Iconic Soccer Jersey Exhibit, Custom ESB Jerseys, Player Visits, Lightings, and More4.6.2026 23:46:00 CEST | Press release

The Empire State Building Observation Deck (ESB) – the #1 Attraction in the United States – today announced further 2026 programming for soccer fans in New York City with the world’s most iconic jersey collection from the Classic Football Shirts (CFS) vault, a limited-edition ESB x CFS jersey, official merch giveaways, and special lightings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604370013/en/ Empire State Building Observation Deck Celebrates Soccer with World’s Most Iconic Soccer Jersey Exhibit, Custom ESB Jerseys, Player Visits, Lightings, and More “As the world descends upon New York City for this anticipated global soccer event, fans can visit the Empire State Building Observation Deck for Manhattan’s best skyline views and a one-of-a-kind soccer exhibit,” said Dan Rogoski, observatory general manager. “International and American soccer fans can extend the celebration off the pitch at the #1 Attraction in the

Vycellix to Provide Universal Cell Cancer Therapy Progress Reports at Upcoming Investor & Partnering Meetings4.6.2026 20:15:00 CEST | Press release

- June events include USA trade mission to Norway (Oslo), the EHA Annual Meeting (Stockholm) and BIO International Convention (San Diego) Vycellix, Inc., a biotechnology company developing next-generation allogeneic natural killer (NK) cell-based therapies designed to overcome the risk of immune rejection and redefine functional persistence with durability, today announced the Company will attend a series of upcoming investor and partnering meetings to share progress reports on the Company’s universal cell therapy platforms and product candidates targeting multiple myeloma, acute myeloid leukemia and urothelial cancers. Vycellix is attending: June 8-9: U.S. Department of Commerce Certified Trade Mission to Norway in Oslo June 11-14: European Hematology Association (EHA) 2026 Congress in Stockholm June 22-25: BIO International Convention in San Diego (Florida Pavilion, Booth# 1319) To request a meeting with Vycellix at any of these events, please contact Doug Calder at dcalder@vycellix.

Sodali & Co Appoints Fabio Bianconi as Head of Italy4.6.2026 19:15:00 CEST | Press release

Sodali & Co, the leading global capital markets-centric stakeholder advisory firm, today announced the appointment of Fabio Bianconi as Head of Italy, effective immediately. Fabio succeeds Andrea Di Segni, who will transition into a new role as Senior Relationship Advisor, where he will continue to support key client relationships and strategic initiatives across the firm. Fabio brings deep experience, strong client relationships, and a track record advising on complex mandates in the Italian market. He will lead Sodali’s continued growth and development in Italy, building on the firm’s established position in the region. Aneliya Crawford, Chief Partnerships Officer & Global Head of Shareholder Advisory of Sodali & Co, said: “Andrea has played a central role in the evolution of Sodali over more than two decades, helping establish the firm as a trusted global advisor in corporate governance and shareholder engagement. He built our Italian business into a leader in the market, as reflect

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye